Results 161 to 170 of about 251,408 (329)

Targeting the complement system in ANCA-associated vasculitis management. [PDF]

Rheumatology (Oxford)
de Groot K.
europepmc   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Mycophenolate Mofetil and Steroid for Treatment of Patients With IgA Nephropathy

Kidney International Reports
Jing Miao, Parikshit Duriseti, Yeshwanter Radhakrishnan, Lisa Vaughan, Fernando C. Fervenza, Ladan Zand   +5 more
doaj   +1 more source

Pemphigus vegetans successfully treated with systemic corticosteroid and rituximab: a rare case report with 15-month follow-up and literature review. [PDF]

Front Immunol
Ji H, Chen L, Chen J.
europepmc   +1 more source

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Annals of Oncology, 2016
H. Bonnefoi, T. Grellety, O. Trédan, M. Saghatchian, F. Dalenc, A. Mailliez, T. Lharidon, P. Cottu, S. Abadie-Lacourtoisie, B. You, M. Mousseau, J. Dauba, F. D. Piano, I. Desmoulins, F. Coussy, N. Madranges, J. Grenier, F. Bidard, C. Proudhon, G. MacGrogan, C. Orsini, M. Pulido, A. Gonçalves   +22 more
semanticscholar   +1 more source

The hidden regulators: Non‐coding RNAs in KMT2A‐rearranged acute lymphoblastic leukemia

International Journal of Cancer, EarlyView.
Abstract Acute lymphoblastic leukemia (ALL) driven by KMT2A rearrangements (KMT2A‐r) is an aggressive hematologic malignancy with poor prognosis and a high incidence in infants. While KMT2A fusion proteins drive leukemogenesis through transcriptional dysregulation, recent discoveries have highlighted the pivotal role of non‐coding RNAs (ncRNAs) in ...
Maria Augusta Poersch, Ana Carolina Rodrigues, Priscila Elias Ferreira Stricker, Alexandre Luiz Korte Azevedo, Daniel Pacheco Bruschi, Jaqueline Carvalho de Oliveira   +5 more
wiley   +1 more source

Granulomatous slack skin presenting as diffuse poikiloderma and necrotic ulcers, with features of granulomatous vasculitis and response to oral prednisone, acitretin, and oral psoralen plus ultraviolet light therapy—A case report

JAAD Case Reports, 2017
Maria Isabel Beatriz Lim Puno, MD, DPDS, Ma. Teresa Ela Dimagiba, MD, FPDS, Ma. Jasmin Jacinto Jamora, MD, FPDS, Filomena Legarda Montinola, MD, FPDS, Patricia Ty Tinio, MD, FPDS   +4 more
doaj   +1 more source

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

Blood, 2016
A. Möricke, M. Zimmermann, M. Valsecchi, M. Stanulla, A. Biondi, G. Mann, F. Locatelli, G. Cazzaniga, F. Niggli, M. Aricò, C. Bartram, A. Attarbaschi, D. Silvestri, R. Beier, G. Basso, R. Ratei, A. Kulozik, L. Lo Nigro, B. Kremens, J. Greiner, R. Parasole, J. Harbott, R. Caruso, A. von Stackelberg, E. Barisone, C. Rössig, V. Conter, M. Schrappe   +27 more
semanticscholar   +1 more source

Frequent achievement of a drug-free state after orthotopic liver transplantation [PDF]

, 1993
Abu-Elmagd, K, Demetris, AJ, Fung, JJ, Nalesnik, M, Nour, B, Ramos, H, Reyes, J, Starzl, TE, Todo, S, Trucco, M, Tzakis, A, Zeevi, A   +11 more
core  

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

International Journal of Cancer, EarlyView.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang, Jing‐jing Sun, Zhi Wan, Xiao‐yu Jing, Xia Guo, Ju Gao   +5 more
wiley   +1 more source